These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33209891)

  • 1. The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.
    Long Q; Feng Y; Liu C; Wu X; Wang H; Yu H; Zhao X; Wang J
    Ann Transl Med; 2020 Oct; 8(20):1311. PubMed ID: 33209891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China.
    Qi F; Hu X; Liu Y; Wang Z; Duan J; Wang J; Dong M
    Chin J Cancer Res; 2019 Oct; 31(5):749-758. PubMed ID: 31814679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study.
    Tolnay E; Ghimessy ÁK; Juhász E; Sztancsik Z; Losonczy G; Dombi P; Vennes Z; Helf L; Csada E; Sárosi V
    Oncol Lett; 2019 Feb; 17(2):1750-1760. PubMed ID: 30675234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
    Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
    Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
    Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
    Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
    Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
    BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
    Nakashima K; Murakami H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
    Mol Clin Oncol; 2016 Nov; 5(5):575-578. PubMed ID: 27900087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience.
    Wu PY; Cheng YM; Shen MR; Chen YC; Huang YF; Chou CY
    Front Oncol; 2020; 10():1095. PubMed ID: 32760668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
    Murakami S; Saito H; Kondo T; Oshita F; Yamada K
    J Exp Ther Oncol; 2019 Dec; 13(2):131-138. PubMed ID: 31881129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.
    Lunacsek OE; Ravelo A; Coutinho AD; Hazard SJ; Green MR; Willey J; Eaddy M; Goertz HP
    Drugs Real World Outcomes; 2016 Sep; 3(3):333-343. PubMed ID: 27747837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
    Zheng X; Wang H; Zhang G; Yan X; Ma Z
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab.
    Naoki K; Takeda Y; Soejima K; Arai D; Naka G; Nagase S; Arimura K; Kanemura T; Ohhira T; Ikeda N
    Oncol Lett; 2017 May; 13(5):3285-3290. PubMed ID: 28521435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
    Liao J; Liu C; Long Q; Wu X; Wang H; Yu H; Sun S; Zhang Y; Lin Y; Zhao X; Wang J
    Front Oncol; 2021; 11():752545. PubMed ID: 34660317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
    Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.